RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px Reminds me of our infection-related work in 2002! https://t.co/XB4Grqb5FC IS it time for an ACE I trial in #covid #cardiotwitter #medtw
Important results to at avoid universal discontinuation of this meds in COVID-19 patients: "It is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk." Zhang, P et al. https://t.co/Xj67BvHie6
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/4QFbFxgWQS
Interesting first look at associations between ACEi/ARB use in COVID19 patients and lowered mortality. Still more to learn about RAS pathway and COVID19. https://t.co/FFyLq2L4tA
@thischarmingham @dris3af @morganmartinez Hey look at that https://t.co/RiGImVGlAJ
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
https://t.co/wi83h2TRve @PeterAttiaMD I'm sure you've seen this...just wanted to share the early data on the ACEI-COVID-19 controversy.
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https:
Retrospective study (n= 1128) shows unadjusted & adjusted mortality benefit in #COVID19 for hypertensive patients on ACEi/ARBs compared to patients on other anti-hypertensives. Please continue to take your pills! @InfectiousDz @V2019N @KrutikaKuppalli
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @doc_ibd: Inpatient Use of ACE Inhibitors and Angiotensin II R Blockers decreased mortality in COVID-19. Sig. interest in whether this w…
Inpatient Use of ACE Inhibitors and Angiotensin II R Blockers decreased mortality in COVID-19. Sig. interest in whether this would be a good thing or not in COVID-19. Will also be important to see if the widespread use of these drugs PREVENTS infection. h
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @rincondesisifo: (Circulation) Uso de IECA y ARA2 en pac con HTA y #COVID19 hospitalizados y riesgo de mortalidad https://t.co/iRkVpyypE…
RT @tak53381102: 米国循環器病学会の雑誌 中国湖北省、COVID-19診断を受けた成人高血圧患者1128人 ACEI/ARB服用者188人と、服用していない940人で比較 全死因死亡リスクは、ACEI/ARB群の方が低かった(調整後HR、0.42;95%CI、0…
RT @julienpotet: Reassuring: large retrospective study in China finds that ACEis (i.e. ramipril) and ARBs (losartan) are associated to lowe…
Very nice study!
RT @DrLoomba: Association of Inpatient Use of ACE Inhibitors and ARB with Mortality .....COVID-19 | Circulation Research https://t.co/90Cl8…
RT @DrLoomba: Association of Inpatient Use of ACE Inhibitors and ARB with Mortality .....COVID-19 | Circulation Research https://t.co/90Cl8…
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
RT @inaki1954: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/qmIoxWpUsw
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/iL5n7oWLz3
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
これって、結構前からウイルスが体内に入るのにace2リセプターを介するから、飲んでたら良いって話ありましたが、、 こういう儲かる薬が絡んできた時点で懐疑心しか残らない。 こう寄生虫役までは許せたけど、これは、、、
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/cXtlx8aiUk
米国循環器病学会の雑誌 中国湖北省、COVID-19診断を受けた成人高血圧患者1128人 ACEI/ARB服用者188人と、服用していない940人で比較 全死因死亡リスクは、ACEI/ARB群の方が低かった(調整後HR、0.42;95%CI、0.19-0.92;P = 0.03)続き https://t.co/gIuAky0J91
We are starting a randomized controlled trial comparing Ramipril versus placebo for prevention of mortality due to COVID-19-- large, multicenter, trial-- waiting for IND approval by FDA @AmerGastroAssn @AASLDPresident @AASLDtweets @SonalKumarMD
Association of Inpatient Use of ACE Inhibitors and ARB with Mortality .....COVID-19 | Circulation Research https://t.co/90Cl8sA4M0
Very important to remember not to be too reactionary. More to come but certainly seems like our professional societies @HFSA @ACCinTouch @AHAScience did the right thing in making the early statements! https://t.co/V3FwaWqOhh
Whoa, this is a bit of big news if real https://t.co/dnu7USSicT
RT @weirdmedicine: Association of Inpatient Use of ACE Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With H…
RT @DrJJJavier: Use of ACE-I and ARB not associated with increase mortality in hospitalized pts with C-19 @BebetoDice @drbentzbrugal http…
RT @srrezaie: IMPORTANT STUDY --> Zhang P et al. Association of Inpatient Use of ACEI/ARBs with 28d Mortality Among Pts with HTN Hospitaliz…
Use of ACE-I and ARB not associated with increase mortality in hospitalized pts with C-19 @BebetoDice @drbentzbrugal https://t.co/LAVbSwOuCQ
RT @Globalbiosec: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortal…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19, in @CircRes https://t.co/X0oyJrdi8X
Interesting data https://t.co/xjPHilD9KS
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/zzK5ELEfXF
RT @Globalbiosec: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortal…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/LU2hlG8Fhf
Inpatient use of ACE inhibitors and ARBs associated with lower mortality in pts with HTN hospitalized with #COVID19. Very nice study. No mention of GI symptoms in these patients (remember ACE2 is expressed in intestines too) but that would be interesting.
RT @jpusanes: 中国からCOVID-19罹患した入院高血圧患者のACEi/ARB使用と全死因死亡率の関係についての後ろ向き試験 未使用に対して使用群の全死因死亡率が低下。 https://t.co/GDVrllrfdm
RT @lilienfeld1: This is a really big deal. Not many things protect against Covid-19 I corresponded with someone looking into the Covid/A…
This is a really big deal. Not many things protect against Covid-19 I corresponded with someone looking into the Covid/ACE receptor as last month, and asked about medications in lowering risk. She said that using them that way make sense to her. https
Uh maybe instead of HCQ everyone should be in an ACEI/ARB...#COVID19 #gdmtworks https://t.co/8CEURtz1ve
Good trial on use of ACEi/ARB in inpatient with #COVID19 https://t.co/rUgs3SNVMW
Association of Inpatient Use of ACE-Is and ARBs with Mortality Among Patients Hospitalized with COVID-19 https://t.co/UBq3Uj4p2M via @doximity
Can we forget about ACEi/ARB and COVID-19 for now? A new study in Circulation may have put the nail in the coffin of widespread fear of using these drugs in COVID patients. https://t.co/rw8nV5ckqH #morethanjustavirus #COVID19 #ccfim @MRothbergMD @CCF_
RT @amitmah19011095: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mor…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With #COVID-19 | Circulation Confusing title. These pts did better on ARBS/ACEIs. ht
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/FYJPq0lJT6
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/8kE4lfXati
RT @UOHIResearch: New study co-authored by Dr. Peter Liu @HeartInstitute evaluates ACE inhibitors and angiotensin II receptor blockers (ARB…
Well that didn't take long... Contradictory data: "Mortality rates for patients with hypertension not taking an ACEi or ARB, taking an ACEi, and taking an ARB were 26.7%, 32.7%, and 30.6%, respectively." https://t.co/GvSup3d6jq
RT @jpusanes: 中国からCOVID-19罹患した入院高血圧患者のACEi/ARB使用と全死因死亡率の関係についての後ろ向き試験 未使用に対して使用群の全死因死亡率が低下。 https://t.co/GDVrllrfdm
中国からCOVID-19罹患した入院高血圧患者のACEi/ARB使用と全死因死亡率の関係についての後ろ向き試験 未使用に対して使用群の全死因死亡率が低下。 https://t.co/GDVrllrfdm
@PeterAttiaMD @jeffosbornez New retrospective studies in COVID-19 patients: ACE inhibitors and ARBs appear to be protective https://t.co/8w3Au3Jp6g https://t.co/DeSZ05Mrwp @bobkaplan
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @Nat_anest: Интересное ретроспективное исследование по ингибиторам АПФ и Covid - 1128 пациентов из 9 госпиталей: *в группу принимающих…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @RosaCorcoy: *️⃣ IECA/ARA2 y mortalidad por #COVID19: de posible ⬆︎de riesgo por mecanismo de acción a ⬇︎de riesgo en estudios observaci…
RT @pharminfotech: The debate continues. What an exemplar for teaching this is going to be!
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @RosaCorcoy: *️⃣ IECA/ARA2 y mortalidad por #COVID19: de posible ⬆︎de riesgo por mecanismo de acción a ⬇︎de riesgo en estudios observaci…
ElectroSIAC recomienda
Reassuring: large retrospective study in China finds that ACEis (i.e. ramipril) and ARBs (losartan) are associated to lower case-fatality in #COVID19 patients with HTN. If you are on ACEi/ARB, don't stop taking them! I'll take my ramipril 10mg with gre
RT @zakkohane: Do ACE inhibitors help/hurt COVID19 outcome? @CircAHA https://t.co/CP1o75ZjP6 Does this retrospective study shift Bayesian-u…
RT @UOHIResearch: New study co-authored by Dr. Peter Liu @HeartInstitute evaluates ACE inhibitors and angiotensin II receptor blockers (ARB…
RT @UOHIResearch: New study co-authored by Dr. Peter Liu @HeartInstitute evaluates ACE inhibitors and angiotensin II receptor blockers (ARB…
Do ACE inhibitors help/hurt COVID19 outcome? @CircAHA https://t.co/CP1o75ZjP6 Does this retrospective study shift Bayesian-update-driven clinicians in Rx behavior? CC @hmkyale @ethanjweiss
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @UOHIResearch: Une nouvelle étude corédigée par le Dr Peter Liu @HeartInstitute évalue les inhibiteurs de l'ECA et les antagonistes de…
Une nouvelle étude corédigée par le Dr Peter Liu @HeartInstitute évalue les inhibiteurs de l'ECA et les antagonistes des récepteurs de l'angiotensine II (ARA) ainsi que le risque de mortalité chez les patients hypertendus atteints de la COVID-19. 📑➡️ htt
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
ACE/ARBs associated with better outcomes in hospitalized patients with COVID. the physiology is complex and it is a retrospective study with the usual limitations but at the very least argues against stopping them routinely https://t.co/mltFtcGCaL
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @UOHIResearch: New study co-authored by Dr. Peter Liu @HeartInstitute evaluates ACE inhibitors and angiotensin II receptor blockers (ARB…
RT @UOHIResearch: New study co-authored by Dr. Peter Liu @HeartInstitute evaluates ACE inhibitors and angiotensin II receptor blockers (ARB…
RT @UOHIResearch: New study co-authored by Dr. Peter Liu @HeartInstitute evaluates ACE inhibitors and angiotensin II receptor blockers (ARB…